Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
76 hedge funds and large institutions have $142M invested in Cascadian Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 8 closing their positions.
221% more call options, than puts
Call options by funds: $273K | Put options by funds: $85K
69% more capital invested
Capital invested by funds: $84.3M → $142M (+$58.1M)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
1% more funds holding
Funds holding: 75 → 76 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$683K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$296K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$177K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$174K |
| 5 |
EWM
Edge Wealth Management
New York
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$827K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$739K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$399K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$337K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$308K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CI
76
Cowen Inc
New York
| – | -$108K | -19,033 | Closed |
|
77
Squarepoint
New York
| – | -$105K | -18,533 | Closed |
|
|
CSS
78
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$1K | -167 | Closed |
|
CASC Hedge Fund Activity: Q3 2016 in Review
76 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q3 2016, worth a combined $142M — up 69% from $84.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CASC positions and 8 closed out — a net gain of 2 holders — while 19 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $683K. The largest seller was EverPoint Asset Management, cutting an estimated $827K.
- 76 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q3 2016, up from 75 in Q2 2016.
- Funds reported $142M of Cascadian Therapeutics, Inc. stock for Q3 2016, up 69% quarter-over-quarter.
- 10 funds opened new Cascadian Therapeutics, Inc. positions in Q3 2016 and 8 closed out, a net change of +2 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $683K added.
- The largest Cascadian Therapeutics, Inc. seller in Q3 2016 was EverPoint Asset Management, an estimated $827K sold.
Based on aggregated 13F filings for Q3 2016.